News

BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca

  • Two additional novel AI-generated targets for chronic kidney disease and idiopathic pulmonary fibrosis discovered using the Benevolent Platform™ selected to enter AstraZeneca’s drug discovery portfolio 
  • Total of five targets selected to date for portfolio-entry in the collaboration, with the potential for future development milestones and sales-based royalty revenues for BenevolentAI

London, 6 October 2022: BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, today announces that AstraZeneca, a global, science-led biopharmaceutical company, has selected an additional two novel targets to enter its drug portfolio, for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF), resulting in two milestone payments to BenevolentAI.

The long-term collaboration, initiated in 2019, combines BenevolentAI’s proprietary AI-enabled drug discovery platform, the Benevolent Platform™, with AstraZeneca’s disease expertise to identify novel targets. The Platform is disease agnostic, meaning it can be applied to any disease and is capable of rapidly generating novel targets at scale. These latest milestones provide additional validation for BenevolentAI’s disease-agnostic approach, which has so far delivered five novel targets to AstraZeneca’s portfolio, two for CKD and three for IPF. The collaboration was also expanded for a further three years into two new disease areas — heart failure and systemic lupus erythematosus — in January 2022. 

Through the collaboration, BenevolentAI integrates AstraZeneca’s data into its biomedical Knowledge Graph, which has the ability to rapidly normalise and contextualise a diverse range of external and internal data from numerous sources including, but not limited to, scientific literature, patents, genetics, chemistry and clinical trials. BenevolentAI and AstraZeneca scientists work side-by-side, using the Platform and Knowledge Graph to interrogate underlying disease mechanisms, frame and test hypotheses and rapidly identify novel targets. New knowledge generated through the disease programmes is also fed back into the Platform, improving the quality of future drug target predictions.

Joanna Shields, Chief Executive Officer at BenevolentAI, commented: “We are pleased that AstraZeneca has selected a further two novel targets from our collaboration to enter its portfolio. These milestones provide repeated validation of BenevolentAI’s drug discovery Platform, which has demonstrated significant momentum in identifying novel targets across a range of therapeutic indications. We look forward to further successes in our collaboration.”

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, commented: "In order to deliver the next wave of life-changing medicines it is important we identify the right drug targets that can transform disease. Our ongoing collaboration with BenevolentAI is helping us to uncover novel rare variants of complex diseases, such as IPF and CKD. By combining the power of AI with human expertise we are bringing new drug targets into our portfolio.” 


Contacts for BenevolentAI:

Media:

Rajin Kang – VP Communications

rajin.kang@benevolent.ai 

Investors:

investors@benevolent.ai 

Fleur Wood – VP Investor Relations

fleur.wood@benevolent.ai 

FTI Consulting:

Ben Atwell, Simon Conway, Victoria Foster Mitchell

BenevolentAI@fticonsulting.com 

+44 (0) 20 3727 1000

About BenevolentAI

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

More Posts

You Might Also Like

News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022